Description
In 2018, Respi DART was added to the DART meeting series in response to a growing need to face the challenges imposed by respiratory diseases such as RSV and influenza. With the onset of the COVID-19 pandemic, the meeting now also heavily focuses on the newest discoveries and advances in vaccine and antiviral drug development against SARS-CoV-2.
HIV DART and RespiDART are scheduled to take place back-to-back with registration discounts available to delegates who are interested in participating in both meetings. The meetings are scheduled to take place in-person, with virtual conference options available in case of increased SARS-CoV-2 incidence.